Hamilton, NJ — August 20, 2020
Sparta Systems, provider of Quality Management System (QMS) platforms TrackWise and TrackWise Digital, has announced that Bright Path Laboratories, a leader in continuous-flow reactor technology, has selected TrackWise Digital as their QMS of the future.
Bright Path Labs will implement TrackWise Digital’s platform for end-to-end quality management, document management and training management.
Bright Path Labs will also leverage the strategic partnership between Sparta and Quartic, and the combined capabilities of TrackWise Digital and the Quartic AI and IoT Platform to gain tighter data integration between manufacturing operations and quality management. Sparta Systems, Quartic.ai and Bright Path Labs share a vision of connecting real-time manufacturing data and quality decisions. Through the Sparta-Quartic partnership, solutions for product review by exception, real-time deviation identification, and other quality system improvements are being developed for Bright Path Labs and the broader life sciences industry.
About Bright Path Laboratories, Inc.
Bright Path Laboratories, Inc. is a commercial stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathlabs.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.